153 related articles for article (PubMed ID: 35029161)
1. Colonoscopy-Related Adverse Events in Patients With Abnormal Stool-Based Tests: A Systematic Review of Literature and Meta-analysis of Outcomes.
Chandan S; Facciorusso A; Yarra P; Khan SR; Ramai D; Mohan BP; Kassab LL; Bilal M; Shaukat A
Am J Gastroenterol; 2022 Mar; 117(3):381-393. PubMed ID: 35029161
[TBL] [Abstract][Full Text] [Related]
2. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Screening Modalities in Colorectal Cancer: A Network Meta-Analysis.
Zhang J; Cheng Z; Ma Y; He C; Lu Y; Zhao Y; Chang X; Zhang Y; Bai Y; Cheng N
Clin Colorectal Cancer; 2017 Dec; 16(4):252-263. PubMed ID: 28687458
[TBL] [Abstract][Full Text] [Related]
4. Post-colonoscopy colorectal cancer: A population-based cohort study of fecal occult blood test-positive colonoscopies.
Denis B; Bertolaso A; Gendre I; Perrin P; Hammas K
Clin Res Hepatol Gastroenterol; 2024 Feb; 48(2):102285. PubMed ID: 38246488
[TBL] [Abstract][Full Text] [Related]
5. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
Tinmouth J; Lansdorp-Vogelaar I; Allison JE
Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
[TBL] [Abstract][Full Text] [Related]
7. Colorectal Cancer screening in ambulatory healthcare service clinics in Abu Dhabi, United Arab Emirates in 2015-2016.
Almansoori A; Alzaabi M; Alketbi L
BMC Cancer; 2021 Aug; 21(1):897. PubMed ID: 34362343
[TBL] [Abstract][Full Text] [Related]
8. Fecal-based colorectal cancer screening among the uninsured in northern Manhattan.
Hillyer GC; Schmitt KM; Freedberg DE; Kramer RA; Su Y; Rosenberg RM; Neugut AI
Am J Prev Med; 2014 Aug; 47(2):182-7. PubMed ID: 24951037
[TBL] [Abstract][Full Text] [Related]
9. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
[TBL] [Abstract][Full Text] [Related]
10. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
12. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting.
Akram A; Juang D; Bustamante R; Liu L; Earles A; Ho SB; Wang-Rodriguez J; Allison JE; Gupta S
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1265-1270.e1. PubMed ID: 28167157
[TBL] [Abstract][Full Text] [Related]
13. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Lin JS; Perdue LA; Henrikson NB; Bean SI; Blasi PR
JAMA; 2021 May; 325(19):1978-1998. PubMed ID: 34003220
[TBL] [Abstract][Full Text] [Related]
14. The association between organised colorectal cancer screening strategies and reduction of its related mortality: a systematic review and meta-analysis.
Ding H; Lin J; Xu Z; Wang HHX; Huang L; Huang J; Wong MCS
BMC Cancer; 2024 Mar; 24(1):365. PubMed ID: 38515013
[TBL] [Abstract][Full Text] [Related]
15. The impact of stratifying by family history in colorectal cancer screening programs.
Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
[TBL] [Abstract][Full Text] [Related]
16. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
[TBL] [Abstract][Full Text] [Related]
17. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality.
D'Andrea E; Ahnen DJ; Sussman DA; Najafzadeh M
Cancer Med; 2020 Jan; 9(2):824-836. PubMed ID: 31777197
[TBL] [Abstract][Full Text] [Related]
18. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests.
Meklin J; SyrjÄnen K; Eskelinen M
Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
